NASDAQ · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · LARGE CAP
BioLife Solutions, Inc. BLFS
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$96.2M
▲ 28.9% vs FY2024
EPS · FY25
$-0.10
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-1.3%
Net margin · FY25
-4.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 96.2M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 5 cents on every revenue dollar this year.
Per share
USD -0.10
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-1.3%
Return on equity, FY2025
ROE
Operating margin-17.3%
Net margin-4.8%
Return on assets-1.1%
Each USD of equity lost 1 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+14.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+8.1%
+14.9%
+31.0%
+29.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years+45.9%
Change, 10 years—
The share count grew 46% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 405.9M
total assets, end of FY2025
Total assetsUSD 405.9M
EquityUSD 371.9M
CashUSD 33.0M
Gross debtUSD 5.0M
Net debtUSD -28.0M
Current ratio5.94×
The company holds more cash than debt.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.1
0.1
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
0.0
−0.0
0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
0.0
0.0
0.0
0.0
0.0
0.0
·
·
Net income $B
−0.0
−0.0
−0.1
−0.1
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.10
−0.44
−1.55
−3.25
−0.23
−0.06
−0.09
−1.56
−0.21
−0.54
−0.35
−0.31
−0.22
−0.33
−0.03
−0.03
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−1.3
−5.9
−19.4
−33.2
−2.6
1.6
−5.7
−980.6
·
−117.8
−37.5
−968.0
·
·
·
·
Shares out B
0.05
0.05
0.00
0.04
0.04
0.03
0.02
0.02
0.01
0.01
0.01
0.01
0.01
0.00
0.07
0.07
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
59 of 59
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed